| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TRRE.2018.11.001 |
| P698 | PubMed publication ID | 30473173 |
| P50 | author | Luuk B Hilbrands | Q56670649 |
| P2093 | author name string | Teun van Gelder | |
| Gerben A J van Boekel | |||
| Eric T Tjwa | |||
| Merel M Tielemans | |||
| P2860 | cites work | Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve gastrectomy | Q48362144 |
| Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium | Q48629550 | ||
| Stricturing Crohn's disease-like colitis in a patient treated with belatacept. | Q49861796 | ||
| Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. | Q51125249 | ||
| Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. | Q51309418 | ||
| Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. | Q51368572 | ||
| Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. | Q51913689 | ||
| Systemic influence of immunosuppressive drugs on small and large bowel transport and barrier function. | Q52899439 | ||
| Gastroparesis. | Q53141244 | ||
| Induction of immunosuppression by microemulsion cyclosporine in liver transplantation. | Q53890423 | ||
| Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. | Q53911174 | ||
| Pharmacokinetics of tacrolimus and cyclosporine in short-bowel syndrome. | Q54275022 | ||
| A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1 | Q57704207 | ||
| Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation | Q59360993 | ||
| Self-management of adrenal insufficiency by rectal hydrocortisone | Q68082816 | ||
| First-pass metabolism of cyclosporin by the gut | Q68326644 | ||
| Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients | Q69031614 | ||
| Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele | Q24595480 | ||
| Sirolimus: a new agent for prevention of renal allograft rejection | Q28372909 | ||
| Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group | Q28374428 | ||
| Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients | Q30418087 | ||
| Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data | Q31004418 | ||
| The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups | Q31945512 | ||
| Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects | Q32039018 | ||
| Clinical pharmacokinetics of everolimus | Q33358752 | ||
| Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities | Q33625396 | ||
| Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis | Q33629374 | ||
| Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. | Q34099716 | ||
| Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients | Q34257909 | ||
| Clinical pharmacokinetics of sirolimus | Q34347243 | ||
| Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration | Q34409942 | ||
| Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation | Q34439272 | ||
| Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers | Q34570866 | ||
| Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients | Q34573738 | ||
| Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil | Q35093212 | ||
| Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract | Q35827133 | ||
| P-glycoprotein-based loperamide-cyclosporine drug interaction at the rat blood-brain barrier: prediction from in vitro studies and extrapolation to humans | Q35840052 | ||
| Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients | Q36025085 | ||
| Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients | Q36093672 | ||
| Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review | Q36257235 | ||
| Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs | Q36442886 | ||
| Silent Colonic Malakoplakia in a Living-Donor Kidney Transplant Recipient Diagnosed during Annual Medical Examination | Q36824389 | ||
| Rapamycin Inhibition of mTOR Reduces Levels of the Na+/H+ Exchanger 3 in Intestines of Mice and Humans, Leading to Diarrhea | Q36848529 | ||
| Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study | Q36864810 | ||
| Tacrolimus once-daily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients | Q36920641 | ||
| Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. | Q37119638 | ||
| Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation | Q37620393 | ||
| Drug-induced pancreatitis. | Q37982301 | ||
| The effects of gastric bypass surgery on drug absorption and pharmacokinetics | Q38045375 | ||
| Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation | Q38047203 | ||
| From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation | Q38109777 | ||
| The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. | Q38163945 | ||
| Thiopurine-induced pancreatitis in inflammatory bowel diseases. | Q38286123 | ||
| Clinical pharmacokinetics of tacrolimus | Q41096852 | ||
| Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants | Q42168321 | ||
| Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients. | Q42222827 | ||
| Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients | Q42642529 | ||
| Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil | Q42952176 | ||
| Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity | Q43472438 | ||
| Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality | Q43487912 | ||
| Severe life-threatening diarrhea caused by azathioprine but not by 6-mercaptopurine | Q43539596 | ||
| High frequency of ulcers, not associated with Helicobacter pylori, in the stomach in the first year after kidney transplantation | Q43564862 | ||
| Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid | Q43569296 | ||
| ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients | Q43598370 | ||
| Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation | Q43651299 | ||
| Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients | Q43685021 | ||
| Disappearance of measurable mycophenolate mofetil (Cell Cept) in a patient with a renal transplant and an ileostomy | Q43867657 | ||
| Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial | Q43940449 | ||
| Efficacy and pharmacokinetics of tacrolimus oral suspension in pediatric liver transplant recipients. | Q43986508 | ||
| Upper gastrointestinal complications after renal transplantation: a 3-yr sequential study | Q43993060 | ||
| Diabetic ketoacidosis associated with acute pancreatitis in a heart transplant recipient treated with tacrolimus | Q44131843 | ||
| Increased prevalence of gastrointestinal symptoms associated with impaired quality of life in renal transplant recipients | Q44218100 | ||
| A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). | Q44247085 | ||
| Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. | Q44250760 | ||
| Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea | Q44364258 | ||
| Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients | Q44461502 | ||
| Severe villus atrophy and chronic malabsorption induced by azathioprine | Q44477970 | ||
| A case of tacrolimus (FK506)-induced pancreatitis and fatality 2 years postcadaveric renal transplant | Q44527300 | ||
| Dose-adjusted cyclosporine c2 in a patient with jejunoileal bypass as compared to seven other liver transplant recipients. | Q44669316 | ||
| Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study | Q44770918 | ||
| Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens | Q44787212 | ||
| Tacrolimus toxicity associated with concomitant metoclopramide therapy | Q44852187 | ||
| The rate of gastric emptying determines the timing but not the extent of oral tacrolimus absorption: simultaneous measurement of drug exposure and gastric emptying by carbon-14-octanoic acid breath test in stable renal allograft recipients | Q45071155 | ||
| The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil | Q45221758 | ||
| Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy | Q45262234 | ||
| Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy | Q45281317 | ||
| Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. | Q45972840 | ||
| Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. | Q46427135 | ||
| Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil | Q46427167 | ||
| Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial | Q46481287 | ||
| Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy | Q46512714 | ||
| Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium | Q46620913 | ||
| Clinical pharmacokinetics of mycophenolate mofetil | Q46787320 | ||
| Optimal initial dose of orally administered cyclosporine following intravenous cyclosporine therapy | Q46874606 | ||
| Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. | Q46923376 | ||
| Gingival fibroblasts grown from cyclosporin-treated patients show a reduced production of matrix metalloproteinase-1 (MMP-1) compared with normal gingival fibroblasts, and cyclosporin down-regulates the production of MMP-1 stimulated by pro-inflamma | Q46935404 | ||
| Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study. | Q48163053 | ||
| The pharmacokinetics and colonic tissue concentrations of cyclosporine after i.v., oral, and enema administration | Q70179202 | ||
| Bioavailability of prednisolone in patients with intestinal malabsorption: the importance of measuring serum protein-binding | Q71191647 | ||
| Effect of chronic administration of hydrocortisone on the induction and evolution of acute pancreatitis induced by cerulein | Q71536966 | ||
| Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation | Q72409795 | ||
| Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine | Q73009245 | ||
| Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine | Q73253890 | ||
| Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients | Q73265627 | ||
| Mycophenolate mofetil-induced colonic ulceration in renal transplant recipients | Q74616026 | ||
| Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients | Q74779545 | ||
| Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits | Q77470579 | ||
| Sirolimus-induced intractable chronic diarrhea: a case report | Q79781721 | ||
| Oral ulcers produced by mycophenolate mofetil in two liver transplant patients | Q80184975 | ||
| Duodenal villous atrophy: a cause of chronic diarrhea after solid-organ transplantation | Q83384951 | ||
| A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study) | Q84102539 | ||
| Treatment of Helicobacter pylori | Q84982536 | ||
| Two cases of ulcerative colitis developing in rheumatoid arthritis patients during abatacept therapy | Q87555098 | ||
| Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial | Q91527422 | ||
| Iron deficiency anaemia guidelines: time for an update? | Q95807520 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 55-63 | |
| P577 | publication date | 2018-11-14 | |
| P1433 | published in | Transplantation Reviews | Q15749559 |
| P1476 | title | Immunosuppressive drugs and the gastrointestinal tract in renal transplant patients | |
| P478 | volume | 33 |
| Q92031061 | Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions | cites work | P2860 |
Search more.